Biotest

Biotest Gross Margin

Delisted

The Gross Margin of Biotest (BIO.DE) as of Nov 19, 2026 is 30.82 %. In the previous year, Gross Margin was 40.94 % — a change of -24.73% (lower).

Gross Margin

30.82 %

YoY

-24.73%

Last updated:

Gross Margin of Biotest is 2024 30.82 % . Gross Margin of Biotest was 2023 40.94 % . It decreases by -24.73% lower compared to the previous year.

Biotest's gross margin stands at 30.8%, up from 26.9% several years earlier.

The Biotest Gross Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Gross Margin
Date
Gross Margin
Jan 1, 2017
32.66 EUR
Jan 1, 2018
33.67 EUR
Jan 1, 2019
30.73 EUR
Jan 1, 2020
26.87 EUR
Jan 1, 2021
15.65 EUR
Jan 1, 2022
24.20 EUR
Jan 1, 2023
40.94 EUR
Jan 1, 2024
30.82 EUR
The Biotest Gross Margin history
YEARGross MarginYoY
30.82 %-24.73%
40.94 %+69.18%
24.20 %+54.62%
15.65 %-41.75%
26.87 %-12.57%
30.73 %-8.74%
33.67 %+3.10%
32.66 %-11.22%
36.79 %+3.84%
35.43 %-8.15%
38.57 %+9,205.30%
0.41 %-1.23%
0.42 %+5.59%
0.40 %-0.31%
0.40 %-26.74%
0.54 %+4.51%
0.52 %-1.48%
0.53 %+6.49%
0.50 %-6.45%
0.53 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Biotest Stock analysis

What does Biotest do? Biotest AG is an innovative and successful company that operates in the fields of medicine, pharmacy, and biotechnology. It was founded in 1946 by Dr. Carl Adolf Vorherr in Dreieich near Frankfurt am Main. The company's original focus was on the development, production, and distribution of blood plasma products. In the 1950s, Biotest expanded into the field of transfusion medicine and began to clinically examine and process blood from donors. It became a leading manufacturer of concentrate preparations for the treatment of immune deficiencies and blood coagulation disorders in the 1960s. In the 1970s, the company became a leading manufacturer of monoclonal and polyclonal antibodies and an important research and development facility for biotechnological applications. Biotest today is divided into five research and business areas: Hematology & Immunology, Clinical Immunology, Biotherapeutics, Dermatology, and Research and Development. The company is globally present with locations in Europe, North America, Asia, and South America. It employs over 2,500 people and its products are available in more than 90 countries. It invests in research and development to stay at the forefront of technology and improve global health. Biotest is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Biotest stock

Gross Margin of Biotest is 30.82 % in 2024.

Gross Margin of Biotest changed from 40.94 % to 30.82 %, representing a -24.73% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Gross Margin Biotest since 2006 – with annual values, charts, and detailed analysis.

Gross Margin measures the percentage of revenue remaining after COGS. Higher gross margins indicate more efficient production and stronger pricing power.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Gross Margin's Biotest with sector peers and the industry average to assess whether it is attractive.

To evaluate Gross Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Gross Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Biotest

All Key Metrics — Biotest